Sunesis Pharmaceuticals (SNSS) has an average broker rating of 1.67, which is interpreted as a Buy, as rated by 3 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
For the current week, the company shares have a recommendation consensus of Buy. Sunesis Pharmaceuticals (NASDAQ:SNSS): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.60 and $0.55 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.64. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.62, notching a gain of 4.24% for the day. The total traded volume was 241,832 . The stock had closed at $0.59 on the previous day.
In a related news, Parker Geoffrey M., director of Sunesis Pharmaceuticals Inc, executed a transaction worth $4,465 on May 26, 2016. A total of 9,500 shares were purchased at an average price of $0.47. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Companys program is QINPREZOTM (vosaroxin), which is its product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD), which is a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin is an AQD, which is used for the treatment of cancer. MLN2480 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Brutons tyrosine kinase (BTK). PDK1 is a kinase and mediator of PI3K/AKT signaling, which is a pathway involved in cell growth, differentiation, survival and migration.